Advertisement

Neurocritical Care

, Volume 28, Issue 1, pp 12–25 | Cite as

A Systematic Review of Alpha-2 Agonists for Sedation in Mechanically Ventilated Neurocritical Care Patients

  • Alexandre Tran
  • Henrietta Blinder
  • Brian Hutton
  • Shane W. EnglishEmail author
Review Article

Abstract

The use of sedative medications is commonplace in intensive care units (ICUs) and an invaluable clinical tool for the intensive care physician. Sedation for critically ill, mechanically ventilated patients provides an opportunity to reduce anxiety, discomfort as well as ventilator intolerance and dyssynchrony. Alpha-2 agonists in particular have become increasingly popular for use in the neurocritical care population due to their proposed effectiveness in facilitating examinations and procedures as well as reducing the need for adjunctive agents. However, there is a paucity of literature to assess the safety of their use in the neurocritically ill patients, a population that presents unique sensitivities and considerations for management of global and cerebral hemodynamics, agitation and facilitation of neurological assessments. This review assesses the safety and efficacy of alpha-2 agonists for non-procedural sedation in critically ill brain-injured patients on mechanical ventilation. In June 2016, we searched the EMBASE, MEDLINE and CENTRAL Cochrane Databases for randomized controlled trials, prospective and retrospective cohort studies examining neurocritically ill adult patients aged 18 years and older who are on mechanical ventilation and receiving alpha-2 agonists for non-procedural sedation. Primary outcomes of interest include mean arterial pressure (MAP), intracranial pressure (ICP), and cerebral perfusion pressure (CPP). Secondary outcomes include adverse events, duration of mechanical ventilation, 30-day mortality, ICU length of stay, incidence of delirium, and quality of sedation. We identified 17 studies for inclusion, all reporting on dexmedetomidine use, only 7 of which reported on our primary outcomes of interest. We found mixed results with regard to statistically significant changes in ICP, CPP, and MAP but did not find evidence of severe hemodynamic disturbances. However, the studies are notably limited by lack of reporting on sedative and hemodynamic adjuncts. Based on the limited available data, dexmedetomidine does not appear to result in severe, uncompensated hemodynamic disturbances (cerebral or systemic). The validation of an effective and safe agent with reporting of dosing strategy, sedation protocol use, co-interventions administered, and a priori defined adverse events is recommended.

Keywords

Alpha-2 Agonists Dexmedetomidine Neurocritical care Sedation Safety Cerebral Hemodynamics 

Abbreviations

ICU

Intensive care unit

ICP

Intracranial pressure

CPP

Cerebral perfusion pressure

MAP

Mean arterial pressure

PROSPERO

International prospective register of systematic reviews

PRISMA

Preferred reporting items for systematic reviews and meta-analysis

GCS

Glasgow Coma Scale

RASS

Richmond Assessment Scale

SAS

Sedation–Agitation Scale

RSS

Ramsay Sedation Scale

BIS

Bispectral Index

Notes

Acknowledgements

The authors would like to thank Mish Boutet for his assistance in developing the search strategy and Patty Ortiz and Wendy Wu for their assistance with translation of papers.

Funding

The authors did not receive any funding for this project.

Author’s contributions

AT and SE conceived the review idea. AT and HB designed the search strategy with revision by SE and BH. AT, HB, SE and BH designed the protocol. AT and HB participated in screening and data extraction with review by SE. All authors participated in the creation of the manuscript. All authors have read and approved the manuscript.

Complaince with Ethical Standards

Conflict of interest

The authors declare that they have no competing interests.

Supplementary material

12028_2017_388_MOESM1_ESM.docx (20 kb)
Supplementary material 1 (DOCX 20 kb)
12028_2017_388_MOESM2_ESM.docx (20 kb)
Supplementary material 2 (DOCX 20 kb)
12028_2017_388_MOESM3_ESM.docx (15 kb)
Supplementary material 3 (DOCX 16 kb)
12028_2017_388_MOESM4_ESM.docx (14 kb)
Supplementary material 4 (DOCX 15 kb)

References

  1. 1.
    Keegan MT. Sedation in the neurologic intensive care unit. Curr Treat Options Neurol. 2008;10(2):111–25.CrossRefPubMedGoogle Scholar
  2. 2.
    Chen K, Lu Z, Xin YC, Cai Y, Chen Y, Pan SM. Alpha-2 agonists for long-term sedation during mechanical ventilation in critically ill patients. Cochrane Database Syst Rev. 2015;1:cd010269.PubMedGoogle Scholar
  3. 3.
    Roberts DJ, Haroon B, Hall RI. Sedation for critically ill or injured adults in the intensive care unit: a shifting paradigm. Drugs. 2012;72(14):1881–916.CrossRefPubMedGoogle Scholar
  4. 4.
    Devlin JW. The pharmacology of oversedation in mechanically ventilated adults. Curr Opin Crit Care. 2008;14(4):403–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Devlin JW, Mallow-Corbett S, Riker RR. Adverse drug events associated with the use of analgesics, sedatives, and antipsychotics in the intensive care unit. Crit Care Med. 2010;38(6 Suppl):S231–43.CrossRefPubMedGoogle Scholar
  6. 6.
    Paul BS, Paul G. Sedation in neurological intensive care unit. Ann Indian Acad Neurol. 2013;16(2):194–202.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hoy SM, Keating GM. Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation. Drugs. 2011;71(11):1481–501.CrossRefPubMedGoogle Scholar
  8. 8.
    Tsaousi GG, Lamperti M, Bilotta F. Role of Dexmedetomidine for Sedation in Neurocritical Care Patients: a qualitative systematic review and meta-analysis of current evidence. Clin Neuropharmacol. 2016;39(3):144–51.CrossRefPubMedGoogle Scholar
  9. 9.
    Tran A, Blinder H, Hutton B, English S. Alpha-2 agonists for sedation in mechanically ventilated neurocritical care patients: a systematic review protocol. Syst Rev. 2016;5(1):154.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ely EW, Margolin R, Francis J, May L, Truman B, Dittus R, et al. Evaluation of delirium in critically ill patients: validation of the confusion assessment method for the intensive care unit (CAM-ICU). Crit Care Med. 2001;29(7):1370–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Ely EW, Truman B, Shintani A, Thomason JW, Wheeler AP, Gordon S, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA. 2003;289(22):2983–91.CrossRefPubMedGoogle Scholar
  13. 13.
    Ambuel B, Hamlett KW, Marx CM, Blumer JL. Assessing distress in pediatric intensive care environments: the COMFORT scale. J Pediatr Psychol. 1992;17(1):95–109.CrossRefPubMedGoogle Scholar
  14. 14.
    Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The newcastle-ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: The Ottawa Hospital Research Institute; 2013.Google Scholar
  16. 16.
    Aryan HE, Box KW, Ibrahim D, Desiraju U, Ames CP. Safety and efficacy of dexmedetomidine in neurosurgical patients. Brain Inj. 2006;20(8):791–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Erdman MJ, Doepker BA, Gerlach AT, Phillips GS, Elijovich L, Jones GM. A comparison of severe hemodynamic disturbances between dexmedetomidine and propofol for sedation in neurocritical care patients. Crit Care Med. 2014;42(7):1696–702.CrossRefPubMedGoogle Scholar
  18. 18.
    Grille P, Biestro A, Farina G, Miraballes R. Effects of dexmedetomidine on intracranial hemodynamics in severe head injured patients. [Spanish]. Neurocirugia. 2005;16(5):411–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Grof TM, Bledsoe KA. Evaluating the use of dexmedetomidine in neurocritical care patients. Neurocrit Care. 2010;12(3):356–61.CrossRefPubMedGoogle Scholar
  20. 20.
    Hao J, Luo FS, Weng Q, He Y, Liu J, Yang MH, et al. Effects of dexmedetomidine on sedation and beta-endorphin in traumatic brain injury: a comparative study with propofol. Chinese Critical Care Medicine. 2013;25(6):373–6.PubMedGoogle Scholar
  21. 21.
    James ML, Olson DM, Graffagnino C. A pilot study of cerebral and haemodynamic physiological changes during sedation with dexmedetomidine or propofol in patients with acute brain injury. Anaesth Intensive Care. 2012;40(6):949–57.PubMedGoogle Scholar
  22. 22.
    Mirski MA, Lewin IJJ, Ledroux S, Thompson C, Murakami P, Zink EK, et al. Cognitive improvement during continuous sedation in critically ill, awake and responsive patients: the Acute Neurological ICU Sedation Trial (ANIST). Intensive Care Med. 2010;36(9):1505–13.CrossRefPubMedGoogle Scholar
  23. 23.
    Pajoumand M, Kufera JA, Bonds BW, Devabhakthuni S, Boswell S, Hesselton K, et al. Dexmedetomidine as an adjunct for sedation in patients with traumatic brain injury. J Trauma Acute Care Surg. 2016;81(2):345–51.CrossRefPubMedGoogle Scholar
  24. 24.
    Srivastava VK, Agrawal S, Kumar S, Mishra A, Sharma S, Kumar R. Comparison of dexmedetomidine, propofol and midazolam for short-term sedation in postoperatively mechanically ventilated neurosurgical patients. J Clin Diagn Res. 2014;8(9):4–7.Google Scholar
  25. 25.
    Wang X, Ji J, Fen L, Wang A. Effects of dexmedetomidine on cerebral blood flow in critically ill patients with or without traumatic brain injury: a prospective controlled trial. Brain Inj. 2013;27(13–14):1617–22.CrossRefPubMedGoogle Scholar
  26. 26.
    Yokota H, Yokoyama K, Noguchi H, Nishioka T, Umegaki O, Komatsu H, et al. Post-operative dexmedetomidine-based sedation after uneventful intracranial surgery for unruptured cerebral aneurysm: comparison with propofol-based sedation. Neurocrit Care. 2011;14(2):182–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Zhao LH, Shi ZH, Chen GQ, Yin NN, Chen H, Yuan Y, et al. Use of dexmedetomidine for prophylactic analgesia and sedation in patients with delayed extubation after craniotomy: a randomized controlled trial. J Neurosurg Anesthesiol. 2015.Google Scholar
  28. 28.
    Chhangani S, Papadakos P. The use of dexmedetomidine for sedation in patients with traumatic brain injury. Anesthesiology. 2002;97:B20.CrossRefGoogle Scholar
  29. 29.
    Hendry R, Mace B, Riemen K, James M, Olson D, Dombrowski K. Cerebral perfusion pressure using precedex and other sedatives (C3PO). Neurocrit Care. 2015;23:S146.Google Scholar
  30. 30.
    Schomer K, Duby J, Sebat C, Adams J, Louie E. Effect of dexmedetomidine (dex) as an adjunctive treatment for elevated intracranial pressure. Neurocrit Care. 2015;23:S53.Google Scholar
  31. 31.
    Tarabrin O, Shcherbakov S, Gavrychenko D, Mazurenko G. Comparison of dexmedetomidine and propofol for sedation in patients with traumatic brain injury. Crit Care. 2014;18:S150–1.CrossRefGoogle Scholar
  32. 32.
    Paplaskas A, Park L, Pusnik M, Parker D Jr. Does dexmedetomidine reduce opioid requirements in brain injured patients. Crit Care Med. 2015;43(12):162–3.CrossRefGoogle Scholar
  33. 33.
    Carney N, Totten AM, O’Reilly C, Ullman JS, Hawryluk GW, Bell MJ, et al. Guidelines for the management of severe traumatic brain injury, fourth edition. Neurosurgery. 2017;80(1):6–15.Google Scholar
  34. 34.
    Barr J, Fraser GL, Puntillo K, Ely EW, Gelinas C, Dasta JF, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(1):263–306.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Alexandre Tran
    • 1
    • 2
  • Henrietta Blinder
    • 1
  • Brian Hutton
    • 1
    • 3
  • Shane W. English
    • 3
    • 4
    Email author
  1. 1.Department of EpidemiologyUniversity of OttawaOttawaCanada
  2. 2.Division of General SurgeryUniversity of OttawaOttawaCanada
  3. 3.Clinical Epidemiology Program (CEP), Centre for Practice-Changing ResearchThe Ottawa Hospital Research Institute–General CampusOttawaCanada
  4. 4.Department of Medicine (Critical Care)University of OttawaOttawaCanada

Personalised recommendations